Abstract
Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have